Dyslipidemia - Pipeline Review, H2 2016

Date: August 31, 2016
Pages: 339
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: DF9DFD361C0EN
Leaflet:

Download PDF Leaflet

Dyslipidemia - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Dyslipidemia - Pipeline Review, H2 2016’, provides an overview of the Dyslipidemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dyslipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Dyslipidemia
  • The report reviews pipeline therapeutics for Dyslipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Dyslipidemia therapeutics and enlists all their major and minor projects
  • The report assesses Dyslipidemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Dyslipidemia
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Dyslipidemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Dyslipidemia Overview
Therapeutics Development
Dyslipidemia - Therapeutics under Development by Companies
Dyslipidemia - Therapeutics under Investigation by Universities/Institutes
Dyslipidemia - Pipeline Products Glance
Dyslipidemia - Products under Development by Companies
Dyslipidemia - Products under Investigation by Universities/Institutes
Dyslipidemia - Companies Involved in Therapeutics Development
Dyslipidemia - Therapeutics Assessment
Drug Profiles
Dyslipidemia - Dormant Projects
Dyslipidemia - Discontinued Products
Dyslipidemia - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Dyslipidemia, H2 2016
Number of Products under Development for Dyslipidemia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd.1)
Number of Products under Development by Companies, H2 2016 (Contd.2)
Number of Products under Development by Companies, H2 2016 (Contd.3)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd.1)
Products under Development by Companies, H2 2016 (Contd.2)
Products under Development by Companies, H2 2016 (Contd.3)
Products under Development by Companies, H2 2016 (Contd.4)
Products under Development by Companies, H2 2016 (Contd.5)
Products under Development by Companies, H2 2016 (Contd.6)
Products under Development by Companies, H2 2016 (Contd.7)
Products under Investigation by Universities/Institutes, H2 2016
Dyslipidemia - Pipeline by Acasti Pharma Inc., H2 2016
Dyslipidemia - Pipeline by AFFiRiS AG, H2 2016
Dyslipidemia - Pipeline by Akcea Therapeutics Inc, H2 2016
Dyslipidemia - Pipeline by Allergan Plc, H2 2016
Dyslipidemia - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016
Dyslipidemia - Pipeline by Amgen Inc., H2 2016
Dyslipidemia - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016
Dyslipidemia - Pipeline by AstraZeneca Plc, H2 2016
Dyslipidemia - Pipeline by BASF SE, H2 2016
Dyslipidemia - Pipeline by BCWorld Pharm Co. Ltd., H2 2016
Dyslipidemia - Pipeline by BioRestorative Therapies, Inc., H2 2016
Dyslipidemia - Pipeline by Cadila Pharmaceuticals Limited, H2 2016
Dyslipidemia - Pipeline by Cardax, Inc., H2 2016
Dyslipidemia - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2016
Dyslipidemia - Pipeline by Cerenis Therapeutics Holding SA, H2 2016
Dyslipidemia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016
Dyslipidemia - Pipeline by CJ HealthCare Corp., H2 2016
Dyslipidemia - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016
Dyslipidemia - Pipeline by CymaBay Therapeutics, Inc., H2 2016
Dyslipidemia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
Dyslipidemia - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Dyslipidemia - Pipeline by Debiopharm International SA, H2 2016
Dyslipidemia - Pipeline by Eli Lilly and Company, H2 2016
Dyslipidemia - Pipeline by Esperion Therapeutics, Inc., H2 2016
Dyslipidemia - Pipeline by Gemphire Therapeutics Inc., H2 2016
Dyslipidemia - Pipeline by GlaxoSmithKline Plc, H2 2016
Dyslipidemia - Pipeline by Golden Biotechnology Corp., H2 2016
Dyslipidemia - Pipeline by HanAll Biopharma Co., Ltd., H2 2016
Dyslipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016
Dyslipidemia - Pipeline by Huons Co., Ltd., H2 2016
Dyslipidemia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
Dyslipidemia - Pipeline by Innovent Biologics, Inc., H2 2016
Dyslipidemia - Pipeline by IPCA Laboratories Limited, H2 2016
Dyslipidemia - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016
Dyslipidemia - Pipeline by Jenrin Discovery, Inc., H2 2016
Dyslipidemia - Pipeline by JW Pharmaceutical Corporation, H2 2016
Dyslipidemia - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016
Dyslipidemia - Pipeline by Kotobuki Pharmaceutical Co., Ltd., H2 2016
Dyslipidemia - Pipeline by Kowa Company, Ltd., H2 2016
Dyslipidemia - Pipeline by Kymab Limited, H2 2016
Dyslipidemia - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
Dyslipidemia - Pipeline by LG Life Science LTD., H2 2016
Dyslipidemia - Pipeline by Lipicard Technologies Limited, H2 2016
Dyslipidemia - Pipeline by Lipigon Pharmaceuticals AB, H2 2016
Dyslipidemia - Pipeline by LipimetiX Development Inc, H2 2016
Dyslipidemia - Pipeline by Lotus Pharmaceutical Co., Ltd., H2 2016
Dyslipidemia - Pipeline by Matinas BioPharma Holdings, Inc., H2 2016
Dyslipidemia - Pipeline by Merck & Co., Inc., H2 2016
Dyslipidemia - Pipeline by Nimbus Therapeutics, LLC, H2 2016
Dyslipidemia - Pipeline by Nippon Chemiphar Co., Ltd., H2 2016
Dyslipidemia - Pipeline by Omeros Corporation, H2 2016
Dyslipidemia - Pipeline by Pfizer Inc., H2 2016
Dyslipidemia - Pipeline by Pharmena SA, H2 2016
Dyslipidemia - Pipeline by Protalix BioTherapeutics, Inc., H2 2016
Dyslipidemia - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
Dyslipidemia - Pipeline by Sancilio & Company, Inc., H2 2016
Dyslipidemia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Dyslipidemia - Pipeline by Thetis Pharmaceuticals LLC, H2 2016
Dyslipidemia - Pipeline by Torrent Pharmaceuticals Limited, H2 2016
Dyslipidemia - Pipeline by Yuhan Corporation, H2 2016
Dyslipidemia - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Dyslipidemia - Dormant Projects, H2 2016
Dyslipidemia - Dormant Projects (Contd.1), H2 2016
Dyslipidemia - Dormant Projects (Contd.2), H2 2016
Dyslipidemia - Dormant Projects (Contd.3), H2 2016
Dyslipidemia - Dormant Projects (Contd.4), H2 2016
Dyslipidemia - Dormant Projects (Contd.5), H2 2016
Dyslipidemia - Dormant Projects (Contd.6), H2 2016
Dyslipidemia - Dormant Projects (Contd.7), H2 2016
Dyslipidemia - Dormant Projects (Contd.8), H2 2016
Dyslipidemia - Dormant Projects (Contd.9), H2 2016
Dyslipidemia - Dormant Projects (Contd.10), H2 2016
Dyslipidemia - Dormant Projects (Contd.11), H2 2016
Dyslipidemia - Dormant Projects (Contd.12), H2 2016
Dyslipidemia - Dormant Projects (Contd.13), H2 2016
Dyslipidemia - Dormant Projects (Contd.14), H2 2016
Dyslipidemia - Dormant Projects (Contd.15), H2 2016
Dyslipidemia - Dormant Projects (Contd.16), H2 2016
Dyslipidemia - Discontinued Products, H2 2016
Dyslipidemia - Discontinued Products (Contd.1), H2 2016
Dyslipidemia - Discontinued Products (Contd.2), H2 2016
Dyslipidemia - Discontinued Products (Contd.3), H2 2016
Dyslipidemia - Discontinued Products (Contd.4), H2 2016
Dyslipidemia - Discontinued Products (Contd.5), H2 2016


LIST OF FIGURES

Number of Products under Development for Dyslipidemia, H2 2016
Number of Products under Development for Dyslipidemia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Acasti Pharma Inc.
AFFiRiS AG
Akcea Therapeutics Inc
Allergan Plc
Alnylam Pharmaceuticals, Inc.
Amgen Inc.
Arisaph Pharmaceuticals, Inc.
AstraZeneca Plc
BASF SE
BCWorld Pharm Co. Ltd.
BioRestorative Therapies, Inc.
Cadila Pharmaceuticals Limited
Cardax, Inc.
Catabasis Pharmaceuticals, Inc.
Cerenis Therapeutics Holding SA
Chong Kun Dang Pharmaceutical Corp.
CJ HealthCare Corp.
Connexios Life Sciences Pvt. Ltd.
CymaBay Therapeutics, Inc.
Daewoong Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
Debiopharm International SA
Eli Lilly and Company
Esperion Therapeutics, Inc.
Gemphire Therapeutics Inc.
GlaxoSmithKline Plc
Golden Biotechnology Corp.
HanAll Biopharma Co., Ltd.
Hanmi Pharmaceuticals, Co. Ltd.
Huons Co., Ltd.
Hyundai Pharmaceutical Co., Ltd.
Innovent Biologics, Inc.
IPCA Laboratories Limited
Jeil Pharmaceutical Co., Ltd.
Jenrin Discovery, Inc.
JW Pharmaceutical Corporation
Kissei Pharmaceutical Co., Ltd.
Kotobuki Pharmaceutical Co., Ltd.
Kowa Company, Ltd.
Kymab Limited
Kyorin Pharmaceutical Co., Ltd.
LG Life Science LTD.
Lipicard Technologies Limited
Lipigon Pharmaceuticals AB
LipimetiX Development Inc
Lotus Pharmaceutical Co., Ltd.
Matinas BioPharma Holdings, Inc.
Merck & Co., Inc.
Nimbus Therapeutics, LLC
Nippon Chemiphar Co., Ltd.
Omeros Corporation
Pfizer Inc.
Pharmena SA
Protalix BioTherapeutics, Inc.
Regeneron Pharmaceuticals Inc
Sancilio & Company, Inc.
Takeda Pharmaceutical Company Limited
Thetis Pharmaceuticals LLC
Torrent Pharmaceuticals Limited
Yuhan Corporation
Zydus Cadila Healthcare Limited
Skip to top


Mixed Dyslipidemia - Pipeline Review, H2 2014 US$ 1,600.00 Nov, 2014 · 56 pages

Ask Your Question

Dyslipidemia - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: